Tetra Bio-Pharma (TSXV:TBP; OTCQB:TBPMF) released a corporate update regarding a potential benefit from the intellectual property (IP) created within the cannabis health research Chair from the University of New Brunswick.
As quoted in the press release:
As part of the 5-year commitment from Tetra and the New Brunswick Health Research Foundation (NBHRF) to The Chair, Tetra will be offered the IP that will be created by The Chair. This important clause in the collaboration with UNB and NBHRF will enable Tetra to obtain licenses from the UNB based on the IP that will be generated from The Chair.
“The strategic importance that is being placed by the government of New-Brunswick through the NBHRF, as well as UNB itself, to the legitimization of the field of medical cannabis is of great importance for the health of Canadians,” said Bernard Fortier, CEO of Tetra Bio-Pharma. “Tetra shares the same values in terms of gaining a greater and more objective understanding of the medical benefits that can be brought about by cannabinoids, which are key components of the active ingredients found in cannabis. The more research is done, like the one that The Chair is supporting, as well as Tetra’s clinical research aimed at bringing novel drugs and treatments to both humans and animals, the faster treatments will be made available to improve the quality of life of patients around the world.”